Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL431069 | 0.98 | NPSR1 (0.49) | NPSR1TOP1HDAC3HDAC4HDAC1 | |
| SCHEMBL11072301 | 0.98 | NPSR1 (0.49) | NPSR1TOP1HDAC3HDAC4HDAC1 | |
| SCHEMBL13587656 | 0.95 | NPSR1 (0.53) | NPSR1TOP1HDAC3HDAC4HDAC1 | |
| SCHEMBL9310464 | 0.93 | NPSR1 (0.56) | NPSR1TOP1HDAC3HDAC4HDAC1 | |
| SCHEMBL4139139 | 0.89 | NPSR1 (0.44) | NPSR1TOP1HDAC3HDAC4HDAC1 | |
| SCHEMBL431068 | 0.86 | HSP90AA1 (0.38) | NPSR1TOP1HDAC3HDAC4HDAC1 | |
| Potassium Ion SCHEMBL5386445 | 0.84 | HDAC3 (0.46) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL11072297 | 0.84 | HDAC3 (0.50) | NPSR1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10666125 | 0.82 | POLB (0.49) | SMN1; SMN2MAPTALDH1A1PPARGKMT2A | |
| SCHEMBL11663970 | 0.81 | ALDH1A1 (0.42) | NPSR1MAPK1SMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012011128-A1 | PREPARATION OF PROSTAGLANDIN DERIVATIVES | APTUIT LAURUS PRIVATE LIMITED (IN) | 2012-01-26 | — | — | WO | claimed |
| US-7166730-B2 | Process for the preparation of prostaglandin derivatives | FINE TECH LABORATORIES, LTD (IL) | 2007-01-23 | — | — | US | claimed |
| US-7157590-B2 | Chemical intermediate for vision defect drug | FINETECH LABORATORIES LTD. (IL) | 2007-01-02 | — | — | US | claimed |
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | FINETECH LABORATORIES LTD | 2005-09-22 | — | — | US | claimed |
| US-6927300-B2 | Process for the preparation of Latanoprost | FINETECH LABORATORIES LTD (IL) | 2005-08-09 | — | — | US | claimed |
| US-20040171873-A1 | Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives | FINETECH PHARMACEUTICAL LTD. (IL) | 2004-09-02 | — | — | US | claimed |
| EP-1397347-A2 | PREPARATION OF 17-PHENYL- 18, 19, 20- TRINOR-PGF2A AND ITS DERIVATIVES | Finetech Laboratories Ltd. (IL) | 2004-03-17 | — | — | EP | claimed |
| US-20030149294-A1 | Process for the preparation of latanoprost | FINETECH PHARMACEUTICALS LTD. (IL) | 2003-08-07 | — | — | US | claimed |
| WO-2002096868-A2 | PREPARATION OF 17-PHENYL- 18, 19, 20- TRINOR-PGF2A AND ITS DERIVATIVES | FINETECH LABORATORIES LTD. (IL) | 2002-12-05 | — | — | WO | claimed |
| US-20140212441-A1 | PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES, ALLERGIC DISEASES AND AUTOIMMUNE DISEASES | R-TECH UENO, LTD. (JP) | 2014-07-31 | — | — | US | disclosed |
| US-20140194497-A1 | COMPOSITION AND METHOD FOR SCALP AND HAIR TREATMENT | R-TECH UENO, LTD. (JP) | 2014-07-10 | — | — | US | disclosed |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | FINETECH PHARMACEUTICAL LTD. (IL) | 2011-11-24 | — | — | US | disclosed |
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| US-7947740-B2 | Bimatoprost crystalline form I | FINETECH PHARMACEUTICAL LTD (IL) | 2011-05-24 | — | — | US | disclosed |
| US-4140712-A | 20-Hydroxy-prostaglandins | ONO PHARMACEUTICAL COMPANY (JP) | 1979-02-20 | — | — | US | disclosed |
| US-4117119-A | 15-CYCLOBUTYL-PROSTAGLANDINS | ONO PHARMACEUTICAL COMPANY (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4110341-A | Dithio prostaglandin derivatives | ONO PHARMACEUTICAL COMPANY (JP) | 1978-08-29 | — | — | US | disclosed |
| US-4045468-A | GASTRIC ULCERS | ONO PHARMACEUTICAL COMPANY (JA) | 1977-08-30 | — | — | US | disclosed |
| US-4024174-A | MEDICINE | ONO PHARMACEUTICAL COMPANY (JA) | 1977-05-17 | — | — | US | disclosed |
| US-3966792-A | Prostaglandin compounds | ONO PHARMACEUTICAL CO., LTD. (JA) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209337-A1 | Process for the preparation of prostaglandin derivatives | PTGIS, PTGES, PTGIR | NPSR1 514/4885TOP1 2803/4885HDAC3 4201/4885 |
| US-20140194497-A1 | COMPOSITION AND METHOD FOR SCALP AND HAIR TREATMENT | PTGER3, PTGDR2, HSD3B2 | NPSR1 2303/4885TOP1 1422/4885HDAC3 451/4885 |
| US-20040171873-A1 | Process for the preparation of 17-phenyl-18,19,20-thinor-pgf 2a and its derivatives | PTGIS, PTGS2, PTGES2 | NPSR1 2737/4885TOP1 703/4885HDAC3 4672/4885 |
| US-20110288179-A1 | BIMATOPROST CRYSTALLINE FORM I | PTGER1, BBC3, CYP2A7 | NPSR1 1521/4885TOP1 155/4885HDAC3 4064/4885 |
| US-20030149294-A1 | Process for the preparation of latanoprost | PTGIS, PTGIR, PTGES | NPSR1 3462/4885TOP1 1324/4885HDAC3 4542/4885 |
| US-20140212441-A1 | PHARMACEUTICAL COMPOSITION FOR INFLAMMATORY DISEASES, ALLERGIC DISEASES AND AUTOIMMUNE DISEASES | IL5, ALOX5, TSLP | NPSR1 2646/4885TOP1 3624/4885HDAC3 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.